The author reflects on the decision of Martin Shkreli, chief executive officer of pharmaceutical company Turing Pharmaceuticals LLC, to increase the price of pyrimethamine, a 62-year-old generic drug used to treat toxoplasmosis and malaria, from $13.50 to $750.00 per pill.